Skip to main content
SpringerLink
Log in

Risk of Suicidality in Depression with Serotonergic Antidepressants

  • Published:
Annals of Clinical Psychiatry

Abstract

Since depression is a risk factor for suicidal thoughts and behaviors, and since suicidal behaviors are associated with low serotonin activity, are selective serotonin reuptake inhibitors (SSRIs) more effective than other antidepressants in treating suicidality in depressed patients? There is inconclusive evidence for and against this hypothesis. However, all studies suggest that antidepressants are effective treatments of suicidal ideations and behaviors, and SSRIs have been shown to have prophylactic effects in preventing suicidal behaviors. Although some reports suggest that SSRIs might increase suicidal ideations and behaviors, the results of large, double-blind studies do not suggest a causal relationship between pharmacotherapy and the emergence of suicidality. Undertreatment of depression and therapeutic failure are more significant problems with the use of antidepressants in suicidal patients than the risk of using antidepressants in overdose. Prescribing inadequate doses of antidepressants is therefore a source of overlooked risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Black DW, Winokur G: Suicide and psychiatric diagnosis. In: Blumenthal SJ, Kupfer DJ, eds. Suicide over the Life Cycle: Risk Factors, Assessment, and Treatment of Suicidal Patients. Washington, DC: American Psychiatric Press; 1990:135–152

    Google Scholar 

  2. Roose SP, Glassman AH: Delusional depression. In: Georgotas A, Cancro R, eds. Depression and Mania. New York: Elsevier; 1988:76–85

    Google Scholar 

  3. Kasper S, Schindler S, Neumeister A: Risk of suicide in depression and its implication for psychopharmacological treatment. Int Clin Psychopharmacol 1996; 11(2):71–79

    Google Scholar 

  4. Regier DA, Moscicki EK: Reduction of the Suicide Rate in Young People: Progress Review. Washington, DC: US Department of Health and Human Services, Office of the Assistant Secretary of Health; 1987

    Google Scholar 

  5. Roy A: Risk factors for suicide in psychiatric patients. Arch Gen Psychiatry 1982; 39:1089–1095

    Google Scholar 

  6. Stoudemire A, Frank R, Hedemark N, Kamlet M, Blazer D: The economic burden of depression. Gen Hosp Psychiatry 1986; 8:387–394

    Google Scholar 

  7. Henry JA: Epidemiology and relative toxicity of antidepressant drugs. Drug Safety 1997; 16(6):374–390

    Google Scholar 

  8. Simon GE, VonKorff M: Suicide mortality among patients treated for depression in an insured population. Am J Epidemiol 1998; 147(2):155–160

    Google Scholar 

  9. Åsberg M, Thoren P, Traskman L, Bertillsson L, Ringberger V: “Serotonin depression”—A biochemical subgroup within the affective disorder? Science 1976; 191:478–480

    Google Scholar 

  10. Mann JJ, Malone KM: Cerebrospinal fluid amines and higher lethality suicide attempts in depressed inpatient. Psychiatric Clin North Am 1997; 20(3):613–624

    Google Scholar 

  11. Winchel RM, Stanley B, Stanley M: Biochemical aspects of suicide. In: Blumenthal SJ, Kupfer DJ, eds. Suicide over the Life Cycle: Risk Factors, Assessment, and Treatment of Suicidal Patients. Washington, DC: American Psychiatric Press; 1990:97–126

    Google Scholar 

  12. Shaw DM, Camps FE, Eccleston EG: 5–Hydroxytryptamine in the hind-brain of depressive suicides. Br J Psychiatry 1967; 113:1407–1411

    Google Scholar 

  13. Beskow J, Gottfries CG, Roos BE, Winblad B: Determination of monoamine and monoamine metabolites in the human brain: Post mortem studies in a group of suicides and a control group. Acta Psychiatr Scand 1976; 53:7–20

    Google Scholar 

  14. Bourne HR, Bunney WE Jr, Colburn RW, Davis JM, Davis JN, Shaw DM, Coppen AJ: Noradrenaline, 5–hydroxytryptamine, and 5–hydroxindoleacetic acid in the hindbrains of suicidal patients. Lancet 1968; 2:805–809

    Google Scholar 

  15. Pare CMB, Yeung DP, Price K, Stacey RS: 5–Hydroxytryptamine, noradrenaline, and dopamine in brainstem, hypothalamus, and caudate nucleus of controls and of patients committing suicide by coal-gas poisoning. Lancet 1969; 2:133–135

    Google Scholar 

  16. Lloyd KG, Farley IJ, Deck JHN, Hornykiewicz O: Serotonin and 5–hydroxyindoleacetic acid in discrete areas of the brainstem of suicide victims and control patients. Adv Biochem Psychopharmacol 1974; 11:387–397

    Google Scholar 

  17. Stanley M, Virgilio J, Gershon S: Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science 1982; 216:1337–1339

    Google Scholar 

  18. Paul SM, Rehavi M, Skolnick P, Goodwin FK: High affinity binding of antidepressants to a biogenic amine transport site in human brain and platelet: Studies in depression. In: Post RM, Ballenger JC, eds. Neurobiology of Mood Disorders. Baltimore: Williams & Wilkins; 1984:846–853

    Google Scholar 

  19. Perry EK, Marshall EF, Blessed G, Tomlinson BE, Perry RH: Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry 1983; 142:188–192

    Google Scholar 

  20. Crow TJ, Cross AJ, Cooper SJ, Deakin JFW, Ferrier IN, Johnson JA, Joseph MH, Owen F, Poulter M, Lofthouse R, Corsellis JAN, Chambers DR, Blessed G, Perry EK, Perry RH, Tomlinson BE: Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimertype dementia and depression and suicides. Neuropharmacology 1984; 23:1561–1569

    Google Scholar 

  21. Meyerson LR, Wennogle LP, Abel MS, Coupet J, Lippa AS, Rauh CE, Beer B: Human brain receptor alterations in suicide Victims. Pharmacol Biochem Behav 1982; 17:159–163

    Google Scholar 

  22. Stanley M, Mann JJ: Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983; 2:214–216

    Google Scholar 

  23. Mann JJ, Stanley M, McBride PA, McEwen BS: Increased serotonin-2 and beta-1–adrenergic receptor binding in the frontal cortices of suicide victims. Arch Gen Psychiatry 1986; 43:954–959

    Google Scholar 

  24. Meltzer HY, Lowry M: The serotonin hypothesis of depression. In: Meltzer HY, ed. The Third Generation of Progress. New York: Raven; 1987:513–526

    Google Scholar 

  25. Owen F, Cross AJ, Crow TJ, Deakin JFW, Ferrier IN, Lofthouse R, Poulter: Brain 5–HT-2 receptors and suicide. Lancet 1983; 2:1256

    Google Scholar 

  26. Cheetam SC, Cross JA, Crompton MR: Serotonin andGABA function in depressed suicide victims. Abstract, International Conference on NewDirections in Affective Disorders, Jerusalem; 1987

  27. Worthington J, Fava M, Davidson K, Alpert J, Nierenberg AA, Rosenbaum JF: Patterns of improvement in depressive symptoms with fluoxetine treatment. Psychopharmacology 1995; 31(2):223–226

    Google Scholar 

  28. Mullin JM, Pandita-Gunawardena VR, Whitehead AM: A double-blind comparison of fluvoxamine and dothiepin in the treatment of major affective disorder. Br J Clin Pract 1988; 42:51–55

    Google Scholar 

  29. De Wilde J, Mertens C, Fredicson Overo K, Hepfner Peterson HE: Citaloprarn versus mianserin. Acta Psychiatr Scand 1985; 72:89–96

    Google Scholar 

  30. Muijen M, Roy D, Silverstone T, Mehmet A, Christie: A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatr Scand 1988; 78:384–390

    Google Scholar 

  31. Gonella G, Baignoli G, Ecari: Fluvoxamine and imipramine in the treatment of depressive patients: A double-blind controlled study. Curr Med Res Opin 1990; 12(3):177–184

    Google Scholar 

  32. Montgomery S: Reduction of suicidal thoughts with paroxetine in comparison with reference antidepressants and placebo. Eur Neuropsychopharmacol 1995; 5(1):5–13

    Google Scholar 

  33. Sacchetti E, Vita A, Guarneri L, Cornarcchia: The effectiveness of fluoxetine, clomipramine, nortriptyline and desipramine in major depressives with suicidal behavior: Preliminary findings. In: Cassano GB, Akiskal HS, eds. Serotonin-Related Psychiatric Syndromes: Clinical and Therapeutic Links. London: Royal Society of Medicine Services; 1991:47–53

    Google Scholar 

  34. Beasley CM Jr, Dornself BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Helligensteirl JI, Thompson VL, Murphy DJ, Masica DN: Fluoxetine and suicide: Meta-analysis of controlled trials of treatment for depression. Brit Med J 1991; 303(6804):685–692[Erratum. Brit Med J 1991; 303(6808):968]

    Google Scholar 

  35. Tollefson GD, Fawectt J, Winokur G, Beasley CM Jr, Potvin JH, Faries DE, Rampey AH Jr, Sayler ME: Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders. Ann Clin Psychiatry 1993; 5(4):209–224

    Google Scholar 

  36. Moller HJ, Steinmeyer EM: Are serotonergic reuptake inhibitors more potent in reducing suicidality? An empirical study on paroxetine. Eur Neuropsychopharmacol 1994; 4(1):55–59

    Google Scholar 

  37. Nathan RS, Perel JM, Pollock BG, Kupfer DJ: The role of neuropharmacologic selectivity in antidepressant action: Fluvoxamine versus desipramine. J Clin Psychiatry 1990; 51:367–372

    Google Scholar 

  38. Perez A, Ashford JJ: Adouble-blind, randomized comparison of fluvoxamine with mianserin in depressive illness. Cur Med Res Opin 1990; 12:234–241

    Google Scholar 

  39. Verkes RJ, Van der Mast RC, Heingeveld MW, Tuyl JP, Zwinderman AH, Van Kempen GM: Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry 1998; 155(4):543–547

    Google Scholar 

  40. Thies-Flechtner K, Muller-Oerlinghausen B, Seibert W, Walther A, Greil W: Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial. Pharmacopsychiatry 1996; 29(3):103–107

    Google Scholar 

  41. Mann JJ, Kapur S: The emergence of suicidal ideation and behavior during antidepressant pharmacotherapy. Arch Gen Psychiatry 1991; 48(11):1027–1033

    Google Scholar 

  42. Beck AT, Kovacs M, Weissman A: Assessment of suicidal intention: The scale for suicidal ideation. J Consult Clin Psychol 1979; 47:343–352

    Google Scholar 

  43. Isacsson G, Holmgren P, Druid H, Bergman U: The utilization of antidepressants—A key issue in the prevention of suicide: An analysis of 5281 suicides in Sweden during the period 1992-1994. Acta Psychiatr Scand 1997; 96(2):94–100

    Google Scholar 

  44. Molcho A, Stanley M: Antidepressants and suicide risk: Issues of chemical and behavioral toxicity. J Clin Psychopharmacol 1992; 12(2 Suppl): 13s–18s

    Google Scholar 

  45. Detre TP, Jarecki HG: Moderm Psychiatric Treatment. Philadelphia, PA: Lippincott; 1971

    Google Scholar 

  46. Damluji NF, Ferguson JM: Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol 1988; 8:342–349

    Google Scholar 

  47. Soloff PH, George A, Nathan RS, Schulz PM, Perel JM: Paradoxical effects of amitriptyline on borderline patients. Am J Psychiatry 1986; 143:1603–1605

    Google Scholar 

  48. Gardner D, Cowdry R: Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 1985; 142:98–100

    Google Scholar 

  49. Teicher MH, Glod C, Cole JO: Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147:207–210

    Google Scholar 

  50. Fava M, Rosenbaum JF: Suicidality and fluoxetine: Is there a relationship? J Clin Psychiatry 1991; 52(3):108–111

    Google Scholar 

  51. Baldwin D, Bullock T, Montgomery D, Montgomery S: 5–HT reuptake inhibitors, tricyclic antidepressants, and suicidal Behavior. Int Clin Psychopharmacol 1991; 6(Suppl 3):49–56

    Google Scholar 

  52. Banki CM: Prophylactic potential of selective reuptake inhibitors in suicidal patients. Int Clin Psychopharmacol 1995; 9(Suppl 4):61–65

    Google Scholar 

  53. Tollefson GD, Rampey AH Jr, Beasley CM Jr, Enas GG, Potvin JH: Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharamcol 1994; 14(3):163–169

    Google Scholar 

  54. Isacsson G, Bergman U, Rich CL: Antidepressants, depression and suicide: An analysis of the San Diego study. J Affect Disord 1994; 32(4):277–286

    Google Scholar 

  55. Isacsson G, Wasserman D, Bergman U: Self-poisonings with antidepressants and other psychotropics in an urban area of Sweden. Ann Clin Psychiatry 1995; 7(3):113–118

    Google Scholar 

  56. Neutel Cl, Patten SB: Risk of suicide attempts after benzodiazepine and/or antidepressant use. Ann Epidemiol 1997; 7(8):568–574

    Google Scholar 

  57. Beskow J: Suicide and mental disorder in Swedish men. Acta Psychiatr Scand Suppl 1979; 227:1–138

    Google Scholar 

  58. Myers DH, Neal CD: Suicide in psychiatric patients. Br J Psychiatry 1978; 133:38–44

    Google Scholar 

  59. Fava M, Rosenbaum JF: Treatment-emergent side effects of the newer antidepressants. Psychiatric Clin North Am Annu Drug Ther 1996; 3:13–29

    Google Scholar 

  60. Henry JA, Alexander CA, Sener EK: Relative mortality from overdose of antidepressants. B Med J 1995; 310:221–224

    Google Scholar 

  61. Henry JA: Suicide and the cost-effectiveness of antidepressants. Br J Psychiatry 1997; 170(1):88

    Google Scholar 

  62. Stoner SC, Marken PA, Watson WA, Switzer JL, Barber MF, Meyer VL, Sommi RW Jr, Steele MT: Antidepressant overdoses and resultant emergency department services: The impact of SSRIs. Psychopharmacol Bull 1997; 33(4):667–670

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts, 02114

    John D. Matthews & Maurizio Fava

Authors
  1. John D. Matthews
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maurizio Fava
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Matthews, J.D., Fava, M. Risk of Suicidality in Depression with Serotonergic Antidepressants. Ann Clin Psychiatry 12, 43–50 (2000). https://doi.org/10.1023/A:1009027010991

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1009027010991

Search

Navigation